Avoid These Retatrutide Mistakes to MAXIMIZE Weight Loss (Beginner’s Guide)
A clinic-run countdown of nine beginner retatrutide mistakes, from injection sites and protein to dosing, side effect timing and stopping, ending in a pitch for the clinic's coaching.
With Dr. Jones, DC (DC)
Key moments
Tap a moment to play the video from there.
- 1:01Rotate your injection sitesJones says repeating the same spot can cause tissue changes and uneven absorption. He recommends rotating between belly, thigh and back of the arm.
- 1:42Protein intake drops with appetiteHe says reduced hunger on retatrutide leads people to eat too little protein, which he says mimics a plateau. He suggests a daily protein floor tied to target body weight.
- 2:27Baseline and follow-up labsJones argues that without baseline labs you cannot tell what is changing. He lists metabolic, lipid, A1C, thyroid, kidney and liver panels as his clinic's standard.
- 3:41Plateau or misread trial curveHe says weight loss in the phase two trial continued through week 48 at the highest dose. In his view, a flat spell under 6 months is usually not a true plateau.
- 5:00The comparison and blame loopJones describes people comparing their results with others online and then changing many variables at once. He advises running your own protocol on your own timeline.
- 5:59Low versus high starting doseHe cites the 2023 phase two trial as showing comparable week 48 results with fewer GI side effects at lower starting doses. He recommends the lowest effective dose.
- 7:22Side effects peak later than expectedJones says heart rate elevation in the trial peaked around week 24 and was dose dependent. He separates mild early adaptation from symptoms that warrant calling a provider.
- 9:06Stopping early and regainHe cites STEP 1 extension and SURMOUNT-4 figures on weight regained after stopping. He notes retatrutide has no discontinuation data yet and urges planning an exit from day one.
- 10:52Why going alone is the top mistakeJones walks back through the list and says a medical team would address each item. He then describes his clinic's team and its free discovery call.
What the video says
Dr. Jones, DC, who says he coaches patients on GLP-1 drugs and peptide strategies and has lost over 100 lbs himself, counts down nine mistakes he says hold back people using retatrutide. He frames them as drawn from phase two trial data and from his clinic's experience, and he says three of them will surprise viewers.
The early items are practical. He says people should rotate injection sites, because repeating the same spot can lead to tissue changes (lipohypertrophy) and unpredictable absorption. He says low protein intake is the beginner mistake he sees most, since appetite suppression pushes protein down and can feel like a plateau. He also argues for baseline and follow-up labs, citing retatrutide's three receptors, and lists metabolic, lipid, A1C, thyroid, kidney and liver panels.
The middle section covers interpreting progress and dosing. He says many perceived plateaus at week 8 to 10 are misreads, because in the phase two trial he cites, weight loss at the highest dose continued through week 48. He warns against comparing results with other people online. On dosing, he says the same trial, which he places in the New England Journal of Medicine in 2023, found that lower starting doses gave comparable week 48 results with fewer GI side effects, so he advises finding the lowest effective dose.
He then says mild nausea and similar effects in the first weeks are adaptation, but that heart rate elevation in the trial peaked around week 24 and rose with dose. He tells viewers to contact their provider about severe or cardiac symptoms. On stopping, he cites semaglutide and tirzepatide discontinuation trials showing substantial regain, notes there is no retatrutide-specific data yet, and says he assumes the gap would be at least as large.
His top mistake is going it alone. He argues a medical team addresses each earlier item, and the last minutes promote his clinic's free discovery calls, programs and pricing.
On each compound
Retatrutide2:33
Jones describes retatrutide as acting on three receptors, which he says means more systems are in play than with single-pathway GLP-1 drugs. He cites a phase two trial for continued weight loss through week 48, comparable results from lower starting doses, and a dose-dependent heart rate rise peaking around week 24.
See how your DNA reads RetatrutideSemaglutide9:11
Jones cites the STEP 1 extension trial of semaglutide, saying about two thirds of lost weight came back within a year of stopping. He uses it only as a proxy because retatrutide lacks stopping data.
See how your DNA reads SemaglutideTirzepatide9:25
Jones cites the SURMOUNT-4 tirzepatide trial, saying 82% of patients switched to placebo regained at least a quarter of the weight they lost within a year.
See how your DNA reads Tirzepatide“A maintenance plan is a day one conversation, not a day 365 conversation.”
What this video doesn’t settle
- Jones describes trial findings from memory without showing the data, so the week 48, dose comparison and week 24 heart rate claims cannot be checked from the video.
- He says there is no retatrutide-specific discontinuation data, so his expectation of regain rests on semaglutide and tirzepatide trials and his own assumption.
- The video is made by a clinic that sells coaching and medical programs, and it closes with a sales pitch, so the argument that going alone is the top mistake serves that business.
Questions this video answers
Does a higher starting dose of retatrutide work better, according to this video?
Jones says no. He cites the 2023 phase two trial as showing that lower starting doses gave comparable week 48 results with fewer GI side effects. He advises finding the lowest effective dose and holding it.
When does retatrutide's heart rate effect peak, according to Dr. Jones?
He says heart rate elevation in the phase two trial peaked around week 24 and was larger at higher doses, which he links to glucagon receptor activity. He advises flagging cardiac symptoms at weeks 16 to 24 with a prescriber.
Is a few flat weeks on retatrutide a plateau?
Jones says a flat two weeks within the first 6 months is usually not a true plateau. He points to trial data where weight loss continued through week 48, and says real plateaus tend to appear later with a specific cause.
What happens if you stop retatrutide, according to this video?
Jones says there is no retatrutide-specific data yet. He cites semaglutide and tirzepatide trials in which much of the lost weight returned within a year, and says he assumes the same or worse for retatrutide.
Which labs does Dr. Jones recommend before starting retatrutide?
He says his clinic runs metabolic panels, lipid profiles, A1C, a full thyroid panel, and kidney and liver function tests before patients start. He argues a baseline is needed to see what changes.
Video by Dr. Jones, DC on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
